NCT00241085已完成4 期
A Multi-center, Double Blind, Randomized, Parallel Group Study to Evaluate the Effects of Valsartan on Proteinuria in Hypertensive Subjects With Type 2 Diabetes Mellitus
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 392
- 主要终点
- Change from baseline in urinary protein excretion after 30 weeks
研究概览
简要总结
This is a study of whether valsartan affects levels of proteinuria in patients with type 2 diabetes and hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •- Mild to moderate hypertension, Mild renal dysfunction, Type 2 diabetes,
排除标准
- •Pregnant or breast feeding, Type 1 diabetes
- •Other protocol criteria apply
结局指标
主要结局
Change from baseline in urinary protein excretion after 30 weeks
次要结局
- Change from baseline in circulating markers of blood vessel inflammation, insulin resistance, serum creatinine, diabetic control, and proportion of patients who return to normalization of protein excretion after 30 weeks
研究者
相似试验
已完成
3 期
Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With MicroalbuminuriaHypertensionNCT00561964Sanofi241
已完成
4 期
Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes MellitusHypertensionType 2 Diabetes MellitusCoronary Artery DiseaseNCT00982358Charite University, Berlin, Germany121
已完成
3 期
Irbesartan in Type 2 DiabetesMicroalbuminuriaHypertensionType 2 DiabetesNCT00317915Steno Diabetes Center Copenhagen
已完成
2 期
Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive HypertensionSalt-sensitive HypertensionNCT01681576Novartis Pharmaceuticals72
已完成
3 期
Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and HyperlipidemiaHypertension,HyperlipidemiaNCT01918332LG Life Sciences168